Harshal Khanwalkar

发表

Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

K. Joshi, M. Rathos, S. Manohar, 2013, BMC Cancer.

Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers.

H. Gronemeyer, W. Bourguet, A. D. de Lera, 2009, Journal of medicinal chemistry.

Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

K. Joshi, M. Rathos, S. Manohar, 2012, Journal of Translational Medicine.

Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.

H. Goyal, Sharad K Sharma, Rakesh Kumar, 2020, Bioorganic & medicinal chemistry.

Modulation of Retinoic Acid Receptor Subtypes by 5‐ and 8‐Substituted (Naphthalen‐2‐yl)‐based Arotinoids

H. Gronemeyer, R. Álvarez, F. Rodríguez-Barrios, 2015, ChemMedChem.

Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold.

H. Gronemeyer, R. Álvarez, A. D. de Lera, 2014, ACS medicinal chemistry letters.

Highly Potent Naphthofuran‐Based Retinoic Acid Receptor Agonists

H. Gronemeyer, J. Voegel, P. Collette, 2009, ChemMedChem.

Retinoid receptor subtype-selective modulators through synthetic modifications of RARgamma agonists.

H. Gronemeyer, R. Álvarez, A. D. de Lera, 2009, Bioorganic & medicinal chemistry.

New retinoid chemotypes: 9-cis-retinoic acid analogs with hydrophobic rings derived from terpenes as selective RAR agonists.

H. Gronemeyer, R. Álvarez, A. D. de Lera, 2008, Bioorganic & medicinal chemistry.

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008

H. Stunnenberg, L. Altucci, H. Gronemeyer, 2011, Molecular Cancer Therapeutics.

Preclinical Development Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI 5008

H. Stunnenberg, L. Altucci, H. Gronemeyer, 2011 .

Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine

W. Hahn, H. Gronemeyer, E. Voltz, 2011, Molecular Cancer Therapeutics.

Pyrazine Arotinoids with Inverse Agonist Activities on the Retinoid and Rexinoid Receptors

H. Gronemeyer, W. Bourguet, A. D. de Lera, 2009, Chembiochem : a European journal of chemical biology.

Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO.

L. Altucci, H. Gronemeyer, A. Nebbioso, 2009, Cancer cell.

Synthesis and Pharmacological Characterization of Disila‐AM80 (Disila‐tamibarotene) and Disila‐AM580, Silicon Analogues of the RARα‐Selective Retinoid Agonists AM80 (Tamibarotene) and AM580

H. Gronemeyer, R. Tacke, R. Bertermann, 2009, ChemMedChem.

C3 Halogen and C8′′ Substituents on Stilbene Arotinoids Modulate Retinoic Acid Receptor Subtype Function

H. Gronemeyer, R. Álvarez, F. Rodríguez-Barrios, 2009, ChemMedChem.

Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

K. Joshi, M. Rathos, S. Manohar, 2012, Journal of Translational Medicine.